文献速递心境障碍

抑郁症治疗新方向:从快速起效抗抑郁药到个体化干预

Novel approaches in depression treatment: from rapid-acting antidepressants to personalized interventions.
PubMed 文献 · Mol Psychiatry · 2026-06-25

本文综述了重性抑郁障碍(MDD)和难治性抑郁(TRD)的快速起效与个体化治疗进展。超过50%的患者对一线5-羟色胺类抗抑郁药反应不足;裸盖菇素已进入后期试验,SAINT方案获FDA批准用于TRD,ALTO-300试验和基因型指导的个体化干预展现潜力,但盲法、可扩展性和生物标志物验证仍是挑战。

要点

  • 超过50%的MDD患者对一线5-羟色胺类抗抑郁药反应不足,快速起效和个体化治疗是未满足需求。
  • SAINT方案已获FDA批准用于TRD,是距临床转化最近的快速起效神经调控干预。
  • 裸盖菇素进入后期试验,ALTO-300试验和基因型指导干预推动个体化治疗,但盲法和生物标志物验证仍是挑战。

核心结论

  • 快速起效和个体化治疗是MDD和TRD的主要未满足需求,多种新干预正推进临床转化。

研究设计与样本

  • 本文为综述,讨论用于MDD和TRD的快速起效与个体化治疗,包括致幻剂和神经可塑性化合物、rTMS个体化方案、ALTO-300试验及基因型指导的2期研究。

主要发现

  • 超过50%的患者对一线5-羟色胺类抗抑郁药反应不足。
  • 裸盖菇素已进入后期试验。
  • SAINT方案已显示快速抗抑郁效应并获FDA批准用于TRD。
  • ALTO-300试验正在评估以EEG生物标志物识别患者的辅助治疗。
  • 一项2期研究报告结果随特定基因型序列而异。

关键数值与推荐

  • SAINT方案获FDA批准用于TRD。
  • 超过50%的MDD患者对一线5-羟色胺类抗抑郁药反应不足。

临床怎么用

  • SAINT方案可作为TRD的快速起效神经调控选择,但需考虑密集方案的可扩展性。
  • ALTO-300试验提示EEG生物标志物可用于筛选个体化辅助治疗人群。
  • 基因型指导的个体化干预可能改善特定基因序列患者的结局。

局限性

  • 致幻剂试验存在揭盲问题。
  • 密集神经调控方案面临可扩展性挑战。
  • 需要经验证的生物标志物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Major depressive disorder (MDD) and treatment-resistant depression (TRD) are prevalent and debilitating conditions. Over 50% of patients have inadequate response to first-line serotonergic antidepressants and are left with suboptimal treatment options. Rapid-acting and individually tailored treatments for MDD remain major unmet needs. This review discusses promising rapid-acting treatments, including psychedelic and neuroplastogen compounds, currently under investigation for the treatment of MDD and TRD. Among these, psilocybin has advanced to late-stage trials. In addition, we examine the emerging role of repetitive transcranial magnetic stimulation (rTMS), including novel personalized interventions, such as the Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT) protocol, which has demonstrated rapid antidepressant effects and is now FDA-cleared for TRD, positioning it closest to clinical translation. We also highlight the ongoing ALTO-300 trial, which is evaluating an adjunctive treatment for MDD in patients identified by an EEG biomarker-representing another promising step toward personalized treatment. Finally, we review the results of a Phase 2 study reporting outcomes that vary by a specific genotype sequence, underscoring the potential for genetically guided personalized interventions. Despite these advances, key limitations, including unblinding in psychedelic trials, scalability challenges of intensive neuromodulation protocols, and the need for validated biomarkers, pose ongoing challenges for real-world implementation.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Guidetti C, Fava M, Papakostas GI, et al. Novel approaches in depression treatment: from rapid-acting antidepressants to personalized interventions. Mol Psychiatry. 2026. PMID: 42350785. doi:10.1038/s41380-026-03722-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。